1 / 27

Clinical importance of interactions

Clinical importance of interactions. Interactions. = when administration of 1 drug ( specific type of food ) influences by any way the effect of another drug result of interaction is : - quantitative change - qualitative change of organism response to drug. Interactions.

theo
Download Presentation

Clinical importance of interactions

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Clinical importance of interactions

  2. Interactions = whenadministrationof 1 drug (specific type offood) influences by anywaytheeffectofanotherdrug resultofinteractionis: - quantitativechange - qualitativechange oforganismresponse to drug

  3. Interactions Possitive interaction: summation 1+1=2 potentiation 1+1=3 Negative interaction: decreased effect

  4. Interactions drug – drug drug – food wanted –  therapeutic effect  toxicity unwanted – most of them, can be reason of ADRs or therapy failure

  5. CombinationsofDrugs wanted: hypertension severe infections TBC malignity unwanted: result in limitation of usage + iatrogenic damage

  6. 5R • Right drug – drug for the diagnosis • Right dose – estimated therapeutic dose • Right time – drugs at developped disease loose effectivity • Right form - drugs as insulin must be administered as s.c. injection, if administered perorally, they dissolve in GIT • Right patient – is the one who needs the drug and we know his risk profile

  7. Factors Increasing Risk of Drug Interactions • Polypharmacy • Polymorbidity • Treatment lasting long time • Chronic disease • Combination of drugs with similar effect • Low therapeutic index • Simultaneous ordination of more drugs by different physicians • Abuses • Self-treatment

  8. Drug with Risk narrow therapeutic window (digoxin, teophylline) steep dose-response curve (warfarin, sulhonylurea der.) enzyme inhibitors (ketoconazole, erythromycin) enzyme inducers (rifampicin, carbamazepine) high toxic potential (aminoglycosides) Patient with Risk polymorbidity polypharmacy disorders of elimination functions abusus non-compliance self-treatment DrugInteractions

  9. Drugs with High Risk • Peroral antidiabetics • Peroral anticoagulants • Heart glykosides • Antiepileptic drugs • Antimanic drugs • NSA • Antibiotics

  10. Division according to the level at which they arise: • pharmaceutic – physical and chemical incompatibility • pharmacocinetic – absorption distribution biotransformation excretion • pharmacodynamic

  11. Absorption • pH in GIT – antacids • motility of GIT – prokinetics antidiarrhoea drugs drugs causing obstipation

  12. Absorption • some drugs in combination with other substances or food form insoluble and non-absorbable complexes /tetracyclines + antacids, black tea + iron/ • reduced absorption of several drugs after milk intake • parenteral administration of vasoconstricting additives – slowing down of absorption from the site of i.m. or s.c. injection

  13. Distribution • Insufficiency of plasmatic proteins – hepatopathy • Binding to plasmatic proteins • Benzodiazepine site • Warfarin site

  14. Distribution • limitation of drug binding to plasma proteins • competitive displacementof substances at biding site – a substance with higher affinity is displacing a substance with a lower affinity to receptors – increasing the portion of free molecules = more intense and shorter effect • mainly substances with high protein binding – more than 90% + with small distribution volume • warfarín, sulfonylurea der.

  15. Biotransformation • the most frequent interactions • some drugs were deregistered for this type of interactions (mibefradil, astemizole, terfenadine...) => serious ADRs, even death • cytochrome P450 – change of activity = change in rate of activation and inactivation of drugs • stimulation of met. = enzyme induction • inhibítion of met. = enzyme inhibítion

  16. Biotransformation Inductors of cyt. P450 - barbiturates, benzodiazepines, hydantoin antiepileptics, glucocortikoids, rifampicin, griseofulvin, St. John´s wort, smoking, grilled meat, chronic alcohol intake – increase biotransformation = decrease the effect of several drugs, e.g. cardiotonics, steroid hormones, coumarin anticoagulants

  17. Biotransformation • Inhibitors of cyt. P450 - some macrolides, quinolones, sulfonamides, some antimycotics (e.g. ketoconazole, fluconazole), isoniazid, metronidazole, chloramphenicol, amiodarone, verapamil, diltiazem, quinidine, SSRI, proton pump inhibitors, cimetidine, garlic, ginkgo, grepefruit juice

  18. PharmacodynamicInteractions • antagonism:opioids-naloxon, benzodiazepines-flumazenil, warfarin-vit. K, caffeine+hypnotics, acetylcholine+atropine neutralization of the effect • synergism:alcohol-antihistamines, antidepressants, ACEI-diuretics, ASA-warfarin, analgesics-antidepressants amplification of the effect

  19. PharmacodynamicInteractions • Most often potentiation of sedative effect on CNS (benzodiasepines and alcohol) • Also potentiation of bradycardia (verapamil a betablockers) • Dangerous simultaneous administration of warfarin and aspirin

  20. InteractionswithAlcohol • Character a intensity  depends on type and ammount  acute, chronic intake • Chronic alcoholism: • Enzyme induction •  absorption and utilization of vitamines • Adaptive changes in neurotransmitters (DOPA system) • Genetic polymorphism - atypical ADH  Japanese, Chinese  sensitivity • Acute intoxication: • Rather inhibits CYP; depents whether the individual is an alcoholic or not

  21. InteractionswithAlcohol • 80-89% of alcohol is metabolized in liver alcohol dehydrogenase(ADH) to acetaldehydethan  aldehyde dehydrogenase (ALDH) to acetate (innoxious acetic acid) • Disulfiraminhibits ALDH=> acetaldehyde => ADRs: tachycardia, feeling hot, nausea and vomiting  effective even 14 days after stopping of treatment

  22. Case Young 35 year old woman, who previously took contraceptive therapy, after a broken leg had thromboembolic events. Followed anticoagulant therapy (warfarin 5 mg; INR - 2.5). At regular controll found hypertriglyceridemia and started was therapy with gemfibrozil 1.2 g daily. Atmenstruation appeared serious bleeding, INR - 4. After reducing warfarin dose to one half (2.5 g), INR was stabilized to 2.5.

  23. Case Gemfibrozil is an inhibitor of CYP3A4 and reduced biotransformation of warfarin, resulting in increased plasma levels of warfarin to values with the risk of bleeding.

More Related